Local Therapy Improves Survival in Lung Cancer Patients
Author Information
Author(s): Su Yuqi, Luo Pan, Ni Ling, Hu Jianbin, Weng Jie, Shen Erdong, Zhou Qiang, Chen Tao, Xiao Jiwen, Xiao Jia, Xie Wangti, Shan Rong, Yao Xiang, Wen Fang
Primary Institution: Yueyang Central Hospital, Yueyang, Hunan, China
Hypothesis
Can local consolidative therapy improve the prognosis of non-small cell lung cancer patients with oligo-residual disease after treatment with PD-1/PD-L1 inhibitors?
Conclusion
Local consolidative therapy may provide additional survival benefits for patients with oligo-residual non-small cell lung cancer after effective PD-1/PD-L1 inhibitors treatment.
Supporting Evidence
- LCT group exhibited significantly longer progression-free survival (PFS) and overall survival (OS) compared to the non-LCT group.
- Patients with 1-2 residual tumor sites benefited significantly from LCT.
- High PD-L1 expression was associated with improved outcomes from LCT.
Takeaway
This study found that giving extra local treatment to some lung cancer patients can help them live longer after their initial treatment.
Methodology
Retrospective analysis of 132 metastatic NSCLC patients treated with PD-1/PD-L1 inhibitors, comparing those who received local consolidative therapy with those who did not.
Potential Biases
Potential selection bias due to the retrospective design and small sample size.
Limitations
The study is retrospective and conducted at a single center, which may introduce selection bias.
Participant Demographics
132 patients, 71 males and 61 females, with a median follow-up of 12 months.
Statistical Information
P-Value
0.017 for PFS, 0.003 for OS
Confidence Interval
95% CI=0.370–0.964 for PFS, 95% CI=0.229–0.949 for OS
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website